Many team members at Unicorn Nest are Ukrainians affected by Russian aggression. We do our best to solve any issues and answer your questions in the shortest possible time frames but some delays are possible.

National Center for Advancing Translational Sciences(NCATS)



Unlock datapoints

Portfolio analytics


News & Media

Add fund to favorites
Save this fund for later to form your own custom list of funds
This summary is composed by our algorithm based on the analysis of the deals. If you think that some of this information is not accurate, please let us know about it and provide any supporting evidences if possible. Such cases will be analyzed by our ML-algorithm and implemented in our database, which will improve this summary.

Need help with fundraising?

We offer an assisted fundraising option for startups

Learn more
Total investments 17
Average round size
The average size of a deal this fund participated in
Portfolio companies 13
Lead investments 4
Follow on index
How often the fund supports its portfolio startups at next rounds
Exits 1
Key employees Soon
Stages of investment

Areas of investment

  • Biotechnology
  • Pharmaceutical
  • Health Care
  • Life Science
  • Education

Besides, a startup needs to be aged 4-5 years to get the investment from the fund. Among the most popular portfolio startups of the fund, we may highlight Hesperos, Intabio, UAMS Translational Research Institute. Among the most popular fund investment industries, there are Association, Biopharma.

Deals in the range of 5 - 10 millions dollars are the general things for fund. The fund is generally included in 2-6 deals every year. The high activity for fund was in 2018.

The standard case for the fund is to invest in rounds with 1 partaker. Despite the National Center for Advancing Translational Sciences(NCATS), startups are often financed by Genoa Ventures. In the next rounds fund is usually obtained by Northpond Ventures, National Institutes of Health, Genoa Ventures.

Read more

Related Funds

Funds investing in previous rounds
These funds often invest in the rounds preceeding the rounds of National Center for Advancing Translational Sciences(NCATS):
Typical Co-investors
National Center for Advancing Translational Sciences(NCATS) is more likely to invest in rounds together with the following funds:
Funds investing in following rounds
These funds have a tendency to invest in the following rounds after National Center for Advancing Translational Sciences(NCATS):
There are no funds here. If we find new data, we will add it here.

Look at other 50 related and similar funds Collapse list
Fund NameLocation
Angels in MedCity England, London, United Kingdom
BellSouth Atlanta, Georgia, United States
BZ Fund Beijing, Beijing, China
Center for Innovative Technology Herndon, United States, Virginia
Deqing Jingshi China, Deqing, Zhejiang
eCAPITAL entrepreneurial Partners AG Germany, Münster, Nordrhein-Westfalen
Flash Forward Ventures United States, Vienna, Virginia
Kamet France, Ile-de-France, Paris
Malik Radix Healthcare Delhi, Delhi, India
Private investors -
Rearden Capital Management LLC -
Scout Analytics Issaquah, United States, Washington
Sichuan Xinhua Distribution Group Chengdu, China, Sichuan
signals Venture Capital Berlin, Berlin, Germany
TechCrunch California, San Francisco, United States
Tempo Beverages Cyprus Ltd. Cyprus, Limassol
Visa Europe England, London, United Kingdom
Waverly Capital -


  • No reviews are submitted yet.
Do you want more?
We provide dozens of additional datapoints about this fund.
Sign up and get access to full fund profile and advanced analysis.
Full team
Industries heatmap
Stages heatmap
Georgaphy breakdown
Portfolio analysis
Performance indexes
Latest highlights
Unlock all data
Do you represent National Center for Advancing Translational Sciences(NCATS)?
Get access to manage this page
Get in touch
Found incorrect info? Let us know!
Total investments 17
Average round size 14M
Peak activity year 2022
Lead investments 4
Follow on index 0.24
Exits 1
Group Appearance index 0.06
Crunchbase icon

Content report

The following text will be sent to our editors: